24th Dec 2015 12:09
LONDON (Alliance News) - GW Pharmaceuticals PLC said Thursday that data on its treatment Epidiolex from a physician-led expanded access programme in treatment resistant epilepsy were published in medical journal The Lancet Neurology.
The published paper reports that the treatment reduced seizure frequency across "multiple drug-resistant epilepsy syndromes and seizure types and was generally well tolerated."
"We are pleased that these Epidiolex data were selected for publication in The Lancet Neurology. The treatment effect seen in this open label study of Epidiolex in our initial target indications of Dravet syndrome and Lennox-Gastaut syndrome shows consistency with other data disclosures, and also demonstrates the effect of Epidiolex across multiple drug-resistant epilepsy syndromes and seizure types," said GW Chief Executive Officer Justin Gover in a statement.
"GW's Phase 3 pivotal safety and efficacy studies in Dravet syndrome and Lennox-Gastaut Syndrome are now nearing completion and will provide the placebo-controlled efficacy and safety profile that patients and physicians have been calling for. We look forward to these results in 2016," Gover added.
Shares in GW Pharmaceuticals were up 5.5% at 396.00 pence Thursday, shortly after midday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L